Glabridin activates the apoptosis pathway by upregulating caspases 3, 8, and 9 to reduce cell viability; it inhibits phosphorylated EGFR, and p-AKT, blocking breast cancer proliferation signals; and lowers intracellular ROS levels, reducing oxidative stress and inhibiting tumor progression. Here, EGFR is linked to breast carcinoma.